Pharmacokinetics and tissue distribution of intraperitoneal 5-fluorouracil with a novel carrier solution in rats

Figure 1 Mean peritoneal fluid volume remaining as a percentage of initial chemotherapy solution volume administered (^aP < 0. 05 between the two carrier solutions).

Figure 2 Mean peritoneal fluid concentration of 5-fluorouracil with different carrier solutions (^aP < 0. 05 between the two carrier solutions).

Figure 3 A: Mean plasma concentration of 5-fluorouracil in portal vein with different carrier solutions (^aP < 0. 05 between the two carrier solutions); B: Mean plasma concentration of 5-fluorouracil in inferior caval vein with different carrier solutions.

Figure 4 A: Mean total quantity of 5-fluorouracil in peritoneal fluid with different carrier solutions (^aP < 0. 05 between the two carrier solutions); B: 5-fluorouracil concentration in gastric tissue with different carrier solutions (^aP < 0.05 between the two carrier solutions); C: 5-fluorouracil concentration in colon tissue with different carrier solutions (^aP < 0.05 between the two carrier solutions); D: 5-fluorouracil concentration in liver tissue with different carrier solutions (^aP < 0.05 between the two carrier solutions); E: 5-fluorouracil concentration in lung tissue with different carrier solutions (^aP < 0.05 between the two carrier solutions); F: 5-fluorouracil concentration in renal tissue with different carrier solutions (^aP < 0.05 between the two carrier solutions).